Immix Biopharma, Inc. is developing tissue-specific therapeutics to treat cancer and inflammatory diseases. The company's pipeline includes IMX-110, in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors, IMX-111, a tissue-specific biologic for the treatment of colorectal cancers, and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. Immix Biopharma was incorporated in 2012 and is headquartered in Los Angeles, CA.
What is Immix Biopharma's quote symbol?
What is the 52 week high and low for Immix Biopharma (NASDAQ: IMMX)?
How much is Immix Biopharma stock worth today?
How much is Immix Biopharma's stock price per share?
What is Immix Biopharma's Market Cap?